All News

gout.bigtoe1.jpg (keep)

New ideas in gout management

d EurekAlert!

Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown.

Read Article
acr_session2.jpeg

EULAR 2025 – Day 3 Report

d Jack Cush, MD

Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.

Read Article
mri-2813908_640.jpg

Imaging and Early Detection in Psoriatic Arthritis

d Antoni Chan, MD, PhD

At EULAR 2025, there have been new developments in imaging in PsA.

Read Article
Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025 https://t.co/S8iA0C4pwG
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 - Day 1 Report Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1. https://t.co/ycQT2dfVXe https://t.co/Qa58ofW411

Links:

Dr. John Cush RheumNow ( View Tweet)
Health Literacy Matters in Rheumatic Disease Care Dr. Mrinalini Dey reports on abstract OP0026, "Health literacy associates with clinical, treatment and work status in people with inflammatory arthritis: Results from a national cohort", presented at EULAR 2025 in Barcelona, https://t.co/f45rxHBYnY
Dr. John Cush RheumNow ( View Tweet)
NMA of 14RCTs (>2500 pts) eval relative efficacy of bDMARDs and tsDMARDs in mostly biologic naïve nr-axSpA pts. -All therapies studied significantly improved ASAS40 response rates compared to placebo. -Certolizumab and Golimumab were the most effective therapies, followed by https://t.co/BJLRpEDYrv

Links:

Adela Castro AdelaCastro222 ( View Tweet)
👁️Uveitis in axSpA: -Up to 40% can present before SpA dx -NMA of 44 RCTs showed tx with TNFi, JAKi and IL-17i protective effects against uveitis -Low rates of uveitis in axSpA pts on BIME trials suggests its possible beneficial effects. #EULAR2025 @RheumNow https://t.co/mPuSMnD1Zs

Links:

Adela Castro AdelaCastro222 ( View Tweet)
In 30 axSpA pts (mean age 42 yrs, BASDAI 3.5, BASFI 2.8, BASMI 2.0, chest expansion 4.5 cm), an 8-wk individualized exercise (cardiorespiratory + trunk strength via cardiopulmonary exercise testing [CPET] & David Back Concept [DBC] devices) ↓ trunk strength deficit 14.1% & https://t.co/505cCEOzu1

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In 631 axSpA pts (mean age 33y, 54% female) from DESIR cohort, high-dose NSAID use (ASAS NSAID index ≥50) not associated with incident hypertension (HR 1.01; 95% CI 0.98–1.02) over 72 months. NSAID anti-inflammatory effect may offset BP risk in axSpA. Abstract#POS0256 @RheumNow https://t.co/ELYWoJDyKJ

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In 4,121 SpA pts (mean age 45y; 61% male), composite scores w/ joint counts (DAPSA, DAS28, DAS44) best discriminated peripheral arthritis activity vs PGA & SJC alone. All scores had excellent construct validity; CRP weakest. Composite indices may optimize SpA assessment. https://t.co/oM97BEkkH5

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In phase II/III trial (NCT04481139), ivarmacitinib 4mg significantly improved PROs in active ankylosing spondylitis: total back pain VAS (-25.6 vs -17.0), night pain (-25.0 vs -14.3), stiffness (-24.5 vs -15.8), PtGA (-23.8 vs -13.3), ASQoL (-3.2 vs -2.4). Benefits seen even https://t.co/RcJ5vfdoHf

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In clinical practice, not all US enthesitis findings are SpA-specific. Enthesophytes/calcifications common in healthy pts. Inflammatory lesions (PD signal, erosions) at Achilles, distal patella & greater trochanter better distinguish PsA/axSpA. Target key sites to improve US https://t.co/jO61QjKfQp

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In 581 PsA pts (EuroSpA), MRI showed axial SpA features in 31%: BME (69%), erosions (68%), fat lesions (58%). MRI-axPsA pts: younger (41y vs 46y), male (70%), HLA-B27+ (55%), ↑CRP (13 vs 7 mg/L). Radiographs identified sacroiliitis in 29%. MRI adds key detection. POS0297 https://t.co/nAw0BDAH22

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Using high-resolution peripheral quantitative computed tomography (HR-pQCT), patients with psoriatic arthritis (PsA) & psoriasis (PsO) show reduced cortical volumetric bone mineral density (vBMD) & thinner cortex vs controls. Bone mechanics impaired: reduced stiffness & failure https://t.co/ghH2cwOYJc

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#Shingrix #vaccination is Impt in #SLE HZ vaccination works in SLE, safe – 1yr still good humeral & cellular immunity -attenuation over 1 yr re #immune #responses No major flares #shingles is ⬆️ in #lupus 👇 abnormal immune response #pred, #MMF #IS POS1005 #EULAR2025 @RheumNow https://t.co/o8lDXgOhE1

Links:

Janet Pope Janetbirdope ( View Tweet)
How does #HCQ work in #SLE Stabilizes lysomal membranes? #Lupus pts on HCQ monoRx & low #SLEDAI were followed Single cell seq HCQ cytokine sigs May vary over time IFN & OXPosph pathways #Hydroxychloroquine in #LN - #IFN I&II #EULAR2025 @RheumNow POS0983 https://t.co/0gMQh9MNlg

Links:

Janet Pope Janetbirdope ( View Tweet)
#TDM for #HCQ warns of #toxic #levels in #CRF v low GFR <30, <60, <90, >90   400mg/d all in low GFR toxic   200mg/d 25% in low GFR toxic   6mg/kg/d – low GFR is too ⬆️ adjust HCQ dose for pts with CRF POS0987 #EULAR2025 @RheumNow @eular_org https://t.co/vg2b87LuiE

Links:

Janet Pope Janetbirdope ( View Tweet)
1/3 of #ERA pts poor Outcomes despite controlled disease! 2 #RCT with T2T in early #RA #CARERA 👇 persistent impact ⬆️TJC, comorbidities ⬇️SJC, CRP, global, HAQ,  F>M ⬆️disease durat’n ▶️ ⬆️ b/tsDMARDs despite =diseaese vs others ?overRx OP0330 #EULAR2025 @RheumNow @eular_org

Janet Pope Janetbirdope ( View Tweet)

×